



**$^{99m}\text{Tc}$ -Glucarate for assessment of paclitaxel therapy in human ovarian cancer in mice**




**Figure S1.** ITLC analysis of mixture reaction after labeling; the percentage of reduced hydrolyzed technetium colloids (RHT) or  $\text{TcO}_2$  was determined ( $R_f = 0$ ) by normal saline as a mobile phase, it was stayed at application point, while  $^{99m}\text{Tc}$ -glucarate was moving in front of mobile phase ( $R_f = 1$ ).

BP = Base line



**Figure S2.**ITLC analysis of mixture reaction after labeling. The percentage of  $^{99m}\text{TcO}_4^-$  was determined ( $R_f = 1$ ) by Methyl ethyl ketone (MEK) as a mobile phase,  $^{99m}\text{Tc}$ -glucarate was moving in front of mobile phase, while  $^{99m}\text{Tc}$ -glucarate was stayed at application point ( $R_f = 0$ ). BP = Base line



**Figure S3.** Radiochemical purity (%) of  $^{99m}\text{Tc}$ -glucarate in solution at different times, it was stabled 98% up to 4 h.